Update on mucosal HIV vaccine vectors

Current Opinion in HIV and AIDS

Volumn 5, Issue 5, 2010, Pages 397-403

  Duerr, Ann ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

HIV vaccine; mucosal vaccine vector; nonhuman primate; simian immunodeficiency virus vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VECTOR;

CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOMEGALOVIRUS; GASTROINTESTINAL MUCOSA; GENITAL SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUTH MUCOSA; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VAGINA MUCOSA; VIRUS TRANSFORMATION;

ADMINISTRATION, MUCOSAL; AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; PRIMATES; VACCINATION;

EID: 77955514904     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833d2e39     Document Type: Review

References (39)

1. Beattie T, Rowland-Jones S, Kaul R. HIV-1 and AIDS: what are protective immune responses? J HIV Ther 2002; 7:35-39.
2. Iwasaki A. Mucosal dendritic cells. Annu Rev Immunol 2007; 25:381-418.
3. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-158.
4. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:S45-S53.
5. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Mucosal vaccination strategies for women. J Infect Dis 1999; 179:S493-S498.
6. Kozlowski PA, Williams SB, Lynch RM, et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002; 169:566574.
7. Moldoveanu Z, Clements ML, Prince SJ, et al. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995; 13:1006-1012.
8. Manrique M, Kozlowski PA, Wang SW, et al. Nasal DNA-MVA SIVvaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol 2009; 2:536-550.
9. Manrique M, Micewicz E, Kozlowski PA, et al. DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. AIDS Res Hum Retroviruses 2008; 24:505-519.
10. Corbett M, Bogers WM, Heeney JL, et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci U S A 2008; 105:2046-2051.
11. Bogers WM, Davis D, Baak I, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008; 382:217-225.
12. Demberg T, Boyer JD, Malkevich N, et al. Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cyto-kines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge. J Virol 2008; 82:10911-10921.
13. Sexton A, De Rose R, Reece JC, et al. Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol 2009; 83:7619-7628.
14. Stahl-Henning C, Kuate S, Franz M, et al. Atraumatic oral spray immunization with replication-deficient viral vectorvaccines. J Virol 2007; 81:13180-13190.
15. Schulte R, Suh YS, Sauermann U, et al. Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques. Virology 2009; 383:300-309.
16. Stolte-Leeb N, Bieler K, Kostler J, et al. Better protective effects in rhesus macaques by combining systemic and mucosal application of a dual component vector vaccine after rectal SHIV89.6P challenge compared to systemic vaccination alone. Viral Immunol 2008; 21:235-246.
17. Earl PL, Americo JL, Wyatt LS, et al. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology 2007; 366:84-97.
18. Vagenas P, Williams VG, Piatak M Jr, et al. Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr 2009; 52:433-442.
19. Mercier GT, Nehete PN, Passeri MF, et al. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 2007; 25:8687-8701.
20. Zhou Q, Hidajat R, Peng B, et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine 2007; 25:8021-8035.
21. Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009; 83:791-801.
22. Wang SW, Bertley FM, Kozlowski PA, et al. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 2004; 20:846-859.
23. Belyakov IM, Kuznetsov VA, Kelsall B, et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. blood 2006; 107:3258-3264.
24. Cranage MP, Fraser CA, Stevens Z, et al. Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol 2010; 3:57-68.
25. Baig J, Levy DB, McKay PF, et al. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol 2002; 76:11484-11490.
26. Fuller DH, Rajakumar PA, Wilson LA, et al. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 2002; 76:3309-3317.
27. Lehner T, Bergmeier LA, Tao L, et al. Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J Immunol 1994; 153:18581868.
28. Stevceva L, Alvarez X, Lackner AA, et al. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8+ T-cell responses in mucosal tissues of macaques. J Virol 2002; 76:116591 1676.
29. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293-299.
30. Wilson NA, Keele BF, Reed JS, et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009; 83:6508-6521.
31. Van Rompay KK, Abel K, Lawson JR, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005; 38:124-134.
32. Kaufman DR, Liu J, Carville A, et al. Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J Immunol 2008; 181:4188-4198.
33. Lemiale F, Kong WP, AkyurekLM, et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 2003; 77:10078-10087.
34. Jespers V, Harandi AM, Hinkula J, et al. Assessment of mucosal immunity to. HIV-1. Expert Rev Vaccines 2010; 9:381-394.
35. Wright PF, Mestecky J, McElrath MJ, et al. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004; 189:1221-1231.
36. Kaufman DR, Barouch DH. Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity. Clin Exp Immunol 2009; 157:165-173.
37. Robert-Guroff M. Replicating and nonreplicating viral vectors for vaccine development. Curr Opin Biotechnol 2007; 18:546-556.
38. McElrath MJ, De Rosa SC, Moodie Z, et al., Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
39. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.